Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19938007 | 0.85 | GBA1 (0.48) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11972565 | 0.79 | — | — | |
| SCHEMBL16780030 | 0.78 | GBA1 (0.57) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL20519453 | 0.77 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL18484868 | 0.76 | — | — | |
| SCHEMBL29838917 | 0.76 | GBA1 (0.42) | GBA1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18680205 | 0.73 | GBA1 (0.41) | GBA1HSD11B1CYP2D6 | |
| SCHEMBL24825915 | 0.72 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL15318697 | 0.72 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17814858 | 0.72 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835533-B2 | 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor | ARRAY BIOPHARMA INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20170087156-A1 | 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | ARRAY BIOPHARMA INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087156-A1 | 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | ARRAY BIOPHARMA INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835533-B2 | 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor | MUSK, CHUK, MAP3K1 | GBA1 4622/4885HSD11B1 3838/4885CYP2D6 4704/4885 |
| US-20170087156-A1 | 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | MUSK, CHUK, MAP3K1 | GBA1 4622/4885HSD11B1 3838/4885CYP2D6 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.